# Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck

> **NCT00513383** · PHASE1 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 34 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** Panitumumab
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **RADIATION:** Intensity Modulated Radiation Therapy
- **DRUG:** 5-Fluorouracil
- **DRUG:** Docetaxel
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT00513383
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2010-10
- **Final completion:** 2012-10
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2017-03-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00513383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00513383, "Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00513383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*